Dr Sikov on the Use of CDK4/6 Inhibitors in the First-line T

William M. Sikov, MD, discusses the negative outcome seen with palbociclib in the phase 3 PALOMA-2 trial, and compares this to data on other CDK4/6 inhibitors in the first-line treatment of estrogen receptor–positive, HER2-negative breast cancers.

Related Keywords

Rhode Island , United States , Williamm Sikov , , Lifespan Educational Advisory Committee , Lifespan Cancer Institute , Infants Hospital , Onclive Tv , Breast Cancer , Cdk4 6 Inhibitors , Her2 Negative Breast Cancers , Hr Positive Breast Cancer ,